Customized treatments enhance breast cancer care
Editor's Note: This article originally appeared in the September/October 2011 issue of Vital Signs.
Not all breast cancers are the same, and tailoring treatments for different types is becoming increasingly common in cancer care. This approach has improved cure rates in some patients and allowed others to avoid unnecessary treatments.
At Providence Regional Cancer Center, medical oncologists utilize various methods to customize therapies. Gene analysis is one technique, which may be used when it’s not clear if a patient’s particular form of breast cancer will benefit from chemotherapy.
“The gene analysis test we use looks at 21 genes and gives us an idea of whether the patient has a low, intermediate or high likelihood of recurrence,” said Maury Blitman, MD, medical oncologist at Providence Regional Cancer Center (pictured left.) “Patients with a high recurrence score will typically benefit from chemotherapy, while those with an intermediate or low recurrence score will not gain additional benefit over the hormonal therapy they have already been prescribed.”
For other breast cancer patients, including the 20 to 25 percent who have what’s known as HER2-positive cancer, “targeted” therapies have shown success. This type of breast cancer occurs when the HER2/neu gene mutates, which can result in cancer that is often less responsive to chemotherapy.
However, says Dr. Blitman, physicians now know that combining chemotherapy with Herceptin®, a drug that specifically targets a protein created by the HER2/neu gene, can improve treatment response and increase cure rates.
As cancer physicians and researchers continue to discover new ways of tailoring treatments, the possibility of curing breast cancer – or at least managing it as a chronic medical condition – is becoming reality.